As seen on:
As seen on:
Latest Articles
A well-built dividend portfolio can generate thousands in passive income — a self-made annual bonus that arrives without clocking in.
Three dividend-paying small caps positioned to capture the Christmas spirit—from chocolate treats to luxury timepieces.
Christmas is here, and there is no better time to count our blessings.
These small-cap REITs yield 7% or more—but are the payouts sustainable?
Three blue-chip stocks have seen their stock price languish, trailing the broader market. Has the market gotten it wrong?
Learn what Free Cash Flow really means, why investors prioritise it over earnings, and how it reveals the true strength of a business.
Popular
UOB’s sharp 72% profit drop hides a proactive balance sheet move – with management assuring dividends remain intact despite higher allowances.
DBS posted record earnings in Q3 2025 as fee income surged and margins held firm. The bank declared a total S$0.75 dividend, underscoring its resilience and steady shareholder returns.
Three Singapore blue-chips are reinventing themselves — and the market may be starting to notice.
DBS Group shares are near record highs after years of stellar growth. With interest rates likely to ease, some investors are wondering if it’s time to cash in. We look at whether the bank’s strong fundamentals still make it worth holding for the long haul.
Stocks
2026 is testing investor conviction, but long-term investing continues to work by leaning on time, business fundamentals, and income rather than prediction.
DBS is a long-term blue-chip favourite, but price still matters — here’s a simple framework to help investors calculate a sensible entry price.
Explore how 3 blue-chip Singapore REITs are pivoting strategies to safeguard unitholder distributions during this upcoming earnings week.
A record-breaking week saw the STI cross 4,900, DBS hit $60, MAS hold policy steady, and Micron commit US$24 billion to expand its Singapore operations.
Getting Started
Will technology stocks remain relevant in the brave new world?
The world faces a different kind of problem aside from the pandemic, but one that can be tackled with pharmaceuticals.
With a potential rocky and unsteady recovery post-COVID-19, here’s how you can locate stocks that will do well.
As enticing and appealing as cash might be, the problem is that there is a cost associated with keeping it.